Mostrar el registro sencillo del ítem

dc.contributor.author
Valenzuela Alvarez, Matias Juan Pablo  
dc.contributor.author
Matos, Bruno  
dc.contributor.author
Correa, Alejandro  
dc.contributor.author
Makiya, Mónica  
dc.contributor.author
Bolontrade, Marcela Fabiana  
dc.date.available
2023-05-23T17:53:17Z  
dc.date.issued
2021  
dc.identifier.citation
Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas; Argentina; 2021; 161-162  
dc.identifier.issn
0025-7680  
dc.identifier.uri
http://hdl.handle.net/11336/198484  
dc.description.abstract
Osteosarcoma (OS), the most common malignant bone tumor, has a 20% five-year survival rate for metastatic disease and treatment-resistant patients. Rapid lung dissemination and acquired chemotherapy resistance remain as major clinical challenges. Mesenchymal stem cells (MSC) may contribute directly or indirectly to OS origin and progression. To identify potential metastasis biomarkers, we made a proteomic screening of non-metastatic SAOS2, metastatic LM7 OS cells and BM-MSC using a shotgun approach by a tandem nanocapillary liquid chromatography-mass spectrometry system. We identified 1049 proteins for BM-MSC, 1567 for SAOS2, and 1424 for LM7. To obtain gene ontology terms of the identified proteins, an enrichment analysis of the gene groups was carried out. The three cell populations shared 661 proteins corresponding to protein metabolism, metabolism, and energy-related pathways (25.72%, 22.37%, and 22.37% respectively). Individually, SAOS2 and LM7 cells showed the same number of shared proteins with BM-MSC, but the 64-shared proteins were not the same. Most relevant differences were that VEGF and PDGF signaling pathways were 2.25 fold-increased in LM7-MSC vs. SAOS2-MSC shared proteins. Further, citric acid and electron transport pathways were upregulated in SAOS2-MSC shared proteins. A comparison between SAOS2 and LM7 also shows upregulation of VEGF/PDGF signaling and other metastatic-related pathways in LM7 cells. Our results on the comparison of both OS cells to MSC, suggest that MSC may have a relevant role in OS progression, dictating not only tumor initiation but also metastatic dissemination. Further, LM7 cells had higher expression levels of proteins related to a mesenchymal phenotype and stem-related genes, suggesting a closer relation with MSC. Lung disease remains a major mortality factor in OS. Identification of mechanisms and differentially expressed genes associated with metastasis would help in discovering promising markers and therapeutic targets.  
dc.format
application/pdf  
dc.language.iso
spa  
dc.publisher
Fundación Revista Medicina  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
OSTEOSARCOMA  
dc.subject
MESENCHYMAL STEM CELLS  
dc.subject
METASTASIS  
dc.subject
BIOMARKERS  
dc.subject.classification
Biotecnología relacionada con la Salud  
dc.subject.classification
Biotecnología de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.type
info:eu-repo/semantics/conferenceObject  
dc.type
info:ar-repo/semantics/documento de conferencia  
dc.date.updated
2022-11-09T18:54:03Z  
dc.journal.pagination
161-162  
dc.journal.pais
Argentina  
dc.journal.ciudad
Buenos Aires  
dc.description.fil
Fil: Valenzuela Alvarez, Matias Juan Pablo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina  
dc.description.fil
Fil: Matos, Bruno. Instituto Carlos Chagas Fiocruz ; Brasil  
dc.description.fil
Fil: Correa, Alejandro. Instituto Carlos Chagas Fiocruz ; Brasil  
dc.description.fil
Fil: Makiya, Mónica. Hospital Italiano; Argentina  
dc.description.fil
Fil: Bolontrade, Marcela Fabiana. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.saic.org.ar/reunion-anual  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.coverage
Internacional  
dc.type.subtype
Reunión  
dc.description.nombreEvento
LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas  
dc.date.evento
2021-11-17  
dc.description.paisEvento
Argentina  
dc.type.publicacion
Journal  
dc.description.institucionOrganizadora
Sociedad Argentina de investigación clínica  
dc.description.institucionOrganizadora
Sociedad Argentina de Inmunología  
dc.description.institucionOrganizadora
Asociación Argentina de Farmacología Experimental  
dc.description.institucionOrganizadora
Asociación Argentina de Nanomedicinas  
dc.source.revista
Medicina (Buenos Aires)  
dc.date.eventoHasta
2021-11-20  
dc.type
Reunión